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In 2003, we began our journey as Editor-in-Chief and
Senior Associate Editor of The American Journal of Pathol-
ogy (AJP), with a Scientific Editor joining us in 2004.
Determined to make a mark on the publishing landscape
of Pathology, we introduced several features. Among our
personal highlights were implementing a strict triage pro-
cess, hiring one of us (A.E.C.) as the Scientific Editor,
subdividing articles into categories, and bringing pub-
lish-ahead-of-print technology to the fore. In the end,
however, our final legacy became the implementation of
a formal Journal Scientific Integrity Policy. Although the
Journal always followed ethical guidelines and princi-
ples and expected our authors and reviewers to do the
same, the generation and publication of a detailed
policy was the natural response to the changing di-
mensions of today’s publishing backdrop.
A Changing Ethical Landscape
When we entered into our editorships, we didn’t antici-
pate that, beyond our desire to attract and publish the
highest quality manuscripts in cellular and molecular
mechanisms of disease, an increasing portion of our time
(admittedly small, even at the end) and mental unease
would be focused on the ethics of our colleagues in
the writing, reviewing, and publishing of scholarship. The
AJP had long required authors to follow the Uniform Re-
quirements for Manuscripts Submitted to Biomedical
Journals prepared by the International Committee of
Medical Journal Editors (http://www.icmje.org). However,
simply asking for adherence was no longer sufficient.
Now to be fair, this scenario wasn’t unique to the AJP or
to the discipline of Pathology. Ethical questions in re-
search and writing have long affected all disciplines.
John Lambert summed it up nicely when he wrote, “It’s a
730strange juncture in the history of moral education when a
student can just as conveniently purchase a term paper
for his or her Business Ethics class as sit down and write
one.” (http://www.highbeam.com/doc/1G1-244246841.
html, last accessed July 11, 2012).
The added challenge is that the ethics are, in fact, a
moving target; one that is highly fluid, often journal-spe-
cific, and open to interpretation. In fact the Public Health
Service (ie, NIH) and the National Science Foundation’s
1990 Final Rule clarified misconduct as “practices that
seriously deviate from those commonly accepted”1 (em-
phasis added); this phrasing was eventually removed
due to its controversial nature. That aside, the question
remaining for us became “Could we define for ourselves
what we term appropriateness?” To do this required the
advice and consent of our stakeholders: the society that
owns the journal (the American Society for Investigative
Pathology), the Publisher (ASIP during our tenure; cur-
rently Elsevier), the editors and editorial board members,
the authors, the readers, the payers of the research (often
the government), other journals that had grappled with
similar issues—the list goes on. We tried to issue best
practice guidelines and modified our Instructions to Au-
thors. We purposely tried to steer a middle ground be-
tween the highly regimented and dogmatic approach
taken by the NIH for handling misconduct to the laissez
faire attitude of many of our competitors.
The Office of Research Integrity (ORI; http://ori.hhs.
gov/documents/rcrintro.pdf, last accessed July 11, 2012)
provides a very clear and concise definition of scientific
misconduct: “fabrication, falsification, or plagiarism in pro-
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research results.” Each type of offense is also defined in
more detail: “Fabrication is making up data or results and
recording or reporting them; falsification is manipulating re-
search materials, equipment, or processes, or changing or
omitting data or results such that the research is not accu-
rately represented in the research record; plagiarism is the
appropriation of another person’s ideas, processes, results,
or words without giving appropriate credit.” These defini-
tions sound easy enough to follow on the surface. The
problems reside in the detection of them. CrossRef has a
plagiarism tool called CrossCheck, developed by iThenti-
cate, which allows manuscripts to be compared to other
papers in its database. The limit to such tools, however, is
the source database itself, relying on journals to allow de-
posit of their materials to be used to search against the
submitted manuscript. Imaging fraud, on the other hand, is
much more difficult to detect.
Imaging Advances or Hindrances?
One notable change that occurred in this millennium re-
volves around the preparation of scientific manuscripts
for submission to journals—the loss of medical illustra-
tions departments. Long gone are the days of submitting
your blots, gels, and graphs to experienced graphic de-
signers who would compose your image panels to pro-
duce photograph copies of the new figure layout, com-
plete with labels. Further, journals no longer accept hard-
copy figures but instead require that all files be submitted
digitally. The tools for preparing figures for publication
now lie in the hands of those performing the research,
whether principle investigator, postdoc, or graduate stu-
dent. Now, the usefulness and power of such tools is
without question, allowing researchers more control over
their figure preparation and saving on outsourcing costs.
However, without proper training—both technical and
ethical—there remains the opportunity for introduction of
innocent errors as well as purposeful manipulation.
Mike Rossner, previous Managing Editor of the Journal
of Cell Biology (JCB), has worked and written extensively
on the issue of image manipulation. In 2002, after the JCB
switched to electronic-only manuscript submission,
Rossner requested that authors and reviewers carefully
look at figures in a digital, rather than printed, manner to
enable magnification of images to expose any improper
manipulation. 2 In a 2004 article,3 he very clearly outlines
the temptations that exist in preparation of images for
publication. He provides explicit examples of the kinds of
image manipulation that can easily be perpetrated with
the use of the tools in Adobe Photoshop. Some of these
deceptions are patently obvious, whereas others are less
easily detectible with the naked eye. For editors and
reviewers, detection of such manipulations can be very
difficult. During our tenure, reviewers and readers occa-
sionally alerted us of such image malfeasance.
There are tools available now to assist in detecting
author malfeasance. One example being droplets, small
applications that allows one to ‘drop and drag’ files for
examining scientific images in excruciating detail at alevel of resolution much greater than the unaided human
eye. With use of this and similar techniques, a skilled user
can detect manipulation of images and areas of discon-
tinuities of gels, dots, and blots, for example. A whole
new lexicon of “solarize edges,” “colorize shapes,” and
“visualize backgrounds” came into use. At one point we
discussed the purchasing and utilization of such forensic
detection tools. We ultimately dropped the idea, as im-
plementing a standard process for assessing all manu-
script images at each round of submission and resub-
mission was not practical at the time.
Implementation of AJP’s Policy
At the end we felt the need to publish a Scientific Integrity
Policy.4 We made use of the myriad resources described
above in addition to others not named here but attributed
in our final policy (http://www.journals.elsevierhealth.com/
periodicals/ajpa/content/integrity; last updated January
2012). We clearly defined such matters as authorship,
ghostwriting, and appropriate and inappropriate image
preparation. The major change in the submission pro-
cess was that we asked our authors on submission to
verify their adherence to a few principles, among them
that the contribution was original and submitted solely to
us, that all persons listed as authors had seen and ap-
proved its submission, and that the ethical guidelines of
the ICMJE and the Journal Scientific Integrity Policy had
been adhered to. Further, because scientific publication
involves external peer review, the Policy also defined the
required conduct of reviewers, editors, and office staff,
thus clarifying our expectations of all parties involved.
Finally, the policy included a section that detailed proce-
dures for handling allegations of misconduct, a section
that has sadly been referred on several occasions.
As the saying goes, however, the devil is in the details.
In one case a person not affiliated with any university or
trained as a scientist had his lawyers contact us to claim
that he actually held the copyright over the intellectual
property presented in a manuscript for which he was not
an author. How could we adjudicate the validity of the
claim? Unfortunately many other examples could be cited
involving plagiarism, dual submissions, salami slicing
(the practice of splitting up what was really one study into
multiple smaller, minimal publishable units to inflate the
number of papers published), and failure to include all
appropriate authors or exclude inappropriate ones (hon-
orific publication).
The most egregious, however, is and was that of falsi-
fying data. During our tenure, we were faced with a situ-
ation involving fabricated patient data together with falsi-
fied supporting figures. After our preliminary assessment,
we turned the case over to the author’s institution, as it is
not a journal’s responsibility to make final determinations
of scientific misconduct. The result of the institution’s
formal investigation was that the lead author did, in fact,
fabricate data, and the institution requested retraction of
the paper. We complied and published a retraction
shortly thereafter.5 Following this, we were contacted by
the institution once again, sadly to inform us that the
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moment for all of those involved. We do not relay this
episode to tell a sensational story but to emphasize the
human element of these cases. The simple allegation of
misconduct has serious implications for a researcher that
are tempered by scientific standing, livelihood, and cul-
tural pressures. It is for this reason that every case must
be handled confidentially, with integrity, and as promptly
as feasible.
The Costs of Rising Scientific Misconduct
So given the threat to one’s reputation and career, why
would anyone gamble with falsifying or fabricating their
data? Ironically, these are the same reasons for commit-
ting scientific/publishing fraud. David Goodstein6 identi-
fied three main motives, or risk factors, that in his expe-
rience appear to influence the offender. “In all of the
cases, the perpetrators i) were under career pressure, ii)
knew, or thought they knew, what the result would be if
they went to all of the trouble of doing the work properly,
and iii) were in a field in which individual experiments are
not expected to be precisely reproducible.” We’re all
aware of the role that tenure practices play in the
journal selection game, trying to find the highest im-
pact factor journal that will publish your manuscript.
Not to mention the pressure of writing grants to secure
funding for one’s lab.
The downstream consequences of scientific miscon-
duct reach well beyond the personal. Case in point, the
long-awaited retraction7 of Wakefield’s autism paper,
which led to an inordinate number of parents not vacci-
nating their children for fear of inducing autism (http://
seedmagazine.com/content/article/the_cost_of_scientific_
misconduct, last accessed July 11, 2012). And the finan-
cial costs associated with investigating scientific miscon-
duct have been reported on extensively. Michalek et al8
categorize the financial impact as the fraudulent research
itself, the ensuing investigation, and the final remediation.
In one case they estimated $525,000 in direct costs, with
indirect costs related to time taken by senior administra-
tive faculty, lost grant funding, transfer of postdocs and
students to new labs (which had to foot the bill), etc totally
over $1 million. And this is just one case; the national
costs of such investigations are hard to imagine.
The public is closely following these matters and no-
ticing what appears to be an increase in retractions and
misconduct cases. Just follow the blog Retraction Watch
(http://retractionwatch.wordpress.com), and you’ll see
daily examples of misconduct allegations, final determi-
nations, and retractions. Of course, one can argue that
with the increase digital savvy of our readers and review-
ers, we are better able to detect such misconduct (just as
the increased knowledge increases the temptation, as
discussed above). But there also appears to be a dis-
connect in scientific ethical culture. In one metaanalysisof fraud surveys, 2% of researchers admitted committing
fraud at least once, and 14% acknowledged seeing it in
their colleagues.9 A recent New York Times article also
highlights the sharp rise in retractions and scientific mis-
conduct (http://www.nytimes.com/2012/04/17/science/rise-
in-scientific-journal-retractions-prompts-calls-for-reform.
html, last accessed July 11, 2012). So what are we as
editors to do?
Final Remarks
Our best defense is to educate our authors, editors, and
reviewers. And then we must deal with these issues as
they arise to the best of our abilities and sensibilities.
Having gone through this difficult exercise, for us the
world didn’t end. We moved on to other assignments and
new opportunities,10 but we would be less than truthful in
saying this did not have a profound effect on us, height-
ening our sensitivity to the importance of our jobs as
editors.11,12 We did not give up on the system (peer
review) or the individuals (scientists who participate in the
creation of new knowledge and its dissemination), and
we maintain our respect for the many thousands of vol-
unteer reviewers and editors who give freely of their time
to assure that the nature of science can be uncovered
through honest assessment and humankind can thus ad-
vance. In the end our goal is to have a “more enduring
impact than encomiums inscribed on a plaque” (http://
www.tabletmag.com/jewish-life-and-religion/87010/turns-
of-praise, last accessed July 11, 2012).
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